Immunoreactivity Analysis of Toxoplasma gondii Recombinant Antigen rSAG3 in Sera from Immunized BALB/c Mice and Toxoplasmosis Patients
-
Mohammad Hossein MOTAZEDIAN
,
Bahram KAZEMI
,
Bahador SHAHRIARI
,
Mojgan BANDEHPOUR
,
Khadijeh KHANALIHA
Abstract
Background: The coccidian protozoa Toxoplasma gondii is an obligate intracellular parasite of humans and other warm-blooded animals. Diagnosis of toxoplasmosis is of considerable medical importance for human, especially pregnant women and immunocompromised individuals. The apply of an Escherichia coli recombinant antigen(s) would be significantly useful in developing standardization of the diagnostic tests and reducing their costs. In this study, immunoreactivity of recombinant SAG3 against sera from immunized mice and human anti-T. gondii IgG positive patients was evaluated by western-blotting and enzyme immunoassay (EIA) in Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences in 2013.
Methods: Three inbreed BALB/c female mice were obtained. Two mice were injected with rSAG3 and one was remained untreated, as control. Sera from immunized mice and also pooled sera from IgG positive toxoplasmosis cases were evaluated with western-blotting. IgG antibody responses to recombinant SAG3 was measured by indirect ELISA against the negative control group.
Results: The rSAG3 protein reacted with sera of immunized mice and sera from patients with anti-Toxoplasma IgG antibodies in western-blot analysis. The result of ELISA showed that, there was marked differences in the absorbance values between the recombinant SAG3 immunized mice and control group.
Conclusion: The rSAG3 showed IgG reactivity with sera from immunized mice and anti-Toxoplasma IgG patients.
Evaluation of a recombinant multiepitope peptide for serodiagnosis of Toxoplasma gondii infection. Clin Vaccine Immunol, 19(3):338-42.
Cesbron-Delauw M-F, Tomavo S, Beauchamps P, et al. (1994). Similarities between the primary structures of two distinct major surface proteins of Toxoplasma gondii. J Biol Chem, 269(23):16217-22.
Boothroyd JC, Hehl A, Knoll LJ, Manger ID (1998). The surface of Toxoplasma: more and less. Int J Parasitol, 28(1):3-9.
Manger ID, Hehl AB, Boothroyd JC (1998). The surface of Toxoplasma tachyzoites is dominated by a family of glycosylphosphatidylinositol-anchored antigens related to SAG1. Infect Immun, 66(5):2237-44.
Jacquet A, Coulon L, De Nève J et al. (2001). The surface antigen SAG3 mediates the attachment of Toxoplasma gondii to cell-surface proteoglycans. Mol Biochem Parasitol, 116(1): 35-44.
Tomavo S (1996). The major surface proteins of Toxoplasma gondii: structures and functions. Curr Top Microbiol Immunol, 219: 45-54.
Lee Y-H, Shin D-W, Lee J-H, Nam H-W, Ahn M-H (2007). Vaccination against murine toxoplasmosis using recombinant Toxoplasma gondii SAG3 antigen alone or in combination with Quil A. Yonsei Med J, 48(3):396-404.
Aubert D, Maine G, Villena I, Hunt J, Howard L, Sheu M, et al. ( 2000). Recombinant antigens to detect Toxoplasma gondii-specific immunoglobulin G and immunoglobulin M in human sera by enzyme immunoassay. J Clin Microbiol, 38(3):1144-50.
Pfrepper K-I, Enders G, Gohl M et al. (2005). Seroreactivity to and avidity for recombinant antigens in toxoplasmosis. Clin Diagn Lab Immunol, 12(8):977-82.
Gatkowska J, Hiszczynska-Sawicka E et al. (2006). Toxoplasma gondii: an evaluation of diagnostic value of recombinant antigens in a murine model. Exp Parasitol, 114(3):220-7.
Kazemi B, Maghen L, Bandehpour M, Shahabi S, Haghighi A (2007). Gene cloning of p43 surface protein of Toxoplasma gondii tachyzoite and bradyzoite (SAG3). Gene Ther Mol Biol, 11:113-6.
Khanaliha K, Motazedian M, Sarkari B, Bandehpour M, Sharifnia Z, Kazemi B (2012). Expression and purification of P43 Toxoplasma gondii surface antigen. Iran J Parasitol, 7(3):48-53.
He X-l, Grigg ME, Boothroyd JC, Garcia KC (2002). Structure of the immunodominant surface antigen from the Toxoplasma gondii SRS superfamily. Nat Struct Biol, 9(8):606-11.
Handman E, Remington JS (1980). Antibody responses to toxoplasma antigens in mice infected with strains of different virulence. Infect Immun, 29(1):215-20.
Cong H, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q, et al. (2013) . Compound DNA vaccine encoding SAG1/SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Parasit Vectors, 6(63): 10.1186/1756-3305-6-63.
Selseleh M, Keshavarz M, Mohebali M et al. (2012). Production and evaluation of Toxoplasma gondii re-combinant surface antigen 1 (SAG1) for serodiagno-sis of acute and chronic Toxoplasma Infection in hu-man sera. Iran J Parasitol, 7(3):1-9.
Selseleh M , Keshavarz M, Mohebali M et al. (2012). Production and evaluation of Toxoplasma gondii re-combinant GRA7 for serodiagnosis of human infec-tions. Korean J Parasitol, 50(3): 233- 38.
Khanaliha K, Motazedian MH, Kazemi B, Bandehpour M, Sharifniya Z (2014). Evaluation of recombinant SAG1, SAG2, and SAG3 antigens for serodiagnosis of toxoplasmosis. Korean J Parasitol, 52(2): 137-42.
| Files | ||
| Issue | Vol 45 No 7 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Immunoreactivity Toxoplasma gondii Recombinant SAG3 Mice | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
